These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 30463049)

  • 1. Pharmacophore-based virtual screening for identification of potential selective inhibitors of human histone deacetylase 6.
    Uba AI; Yelekçi K
    Comput Biol Chem; 2018 Dec; 77():318-330. PubMed ID: 30463049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carboxylic acid derivatives display potential selectivity for human histone deacetylase 6: Structure-based virtual screening, molecular docking and dynamics simulation studies.
    Uba AI; Yelekçi K
    Comput Biol Chem; 2018 Aug; 75():131-142. PubMed ID: 29859380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigation of non-hydroxamate scaffolds against HDAC6 inhibition: A pharmacophore modeling, molecular docking, and molecular dynamics simulation approach.
    Zeb A; Park C; Son M; Rampogu S; Alam SI; Park SJ; Lee KW
    J Bioinform Comput Biol; 2018 Jun; 16(3):1840015. PubMed ID: 29945500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-Based Drug Designing Recommends HDAC6 Inhibitors To Attenuate Microtubule-Associated Tau-Pathogenesis.
    Zeb A; Park C; Rampogu S; Son M; Lee G; Lee KW
    ACS Chem Neurosci; 2019 Mar; 10(3):1326-1335. PubMed ID: 30407786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fragment-Based Drug Design of Selective HDAC6 Inhibitors.
    Ruzic D; Djokovic N; Nikolic K
    Methods Mol Biol; 2021; 2266():155-170. PubMed ID: 33759126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacophore-based virtual screening of ZINC database, molecular modeling and designing new derivatives as potential HDAC6 inhibitors.
    Poonia P; Sharma M; Jha P; Chopra M
    Mol Divers; 2023 Oct; 27(5):2053-2071. PubMed ID: 36214962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of specific HDAC6 inhibitor with anti-metastatic effects in pancreatic cancer cells through virtual screening and biological evaluation.
    Song H; Niu X; Quan J; Li Y; Yuan L; Wang J; Ma C; Ma E
    Bioorg Chem; 2020 Apr; 97():103679. PubMed ID: 32120077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined comparative molecular field analysis, comparative molecular similarity indices analysis, molecular docking and molecular dynamics studies of histone deacetylase 6 inhibitors.
    Sharma M; Jha P; Verma P; Chopra M
    Chem Biol Drug Des; 2019 May; 93(5):910-925. PubMed ID: 30667160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined Ligand and Fragment-based Drug Design of Selective Histone Deacetylase - 6 Inhibitors.
    Ruzic D; Petkovic M; Agbaba D; Ganesan A; Nikolic K
    Mol Inform; 2019 May; 38(5):e1800083. PubMed ID: 30632697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of novel potential selective HDAC8 inhibitors by combine ligand-based, structure-based virtual screening and in-vitro biological evaluation.
    Debnath S; Debnath T; Bhaumik S; Majumdar S; Kalle AM; Aparna V
    Sci Rep; 2019 Nov; 9(1):17174. PubMed ID: 31748509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PTG-0861: A novel HDAC6-selective inhibitor as a therapeutic strategy in acute myeloid leukaemia.
    Gawel JM; Shouksmith AE; Raouf YS; Nawar N; Toutah K; Bukhari S; Manaswiyoungkul P; Olaoye OO; Israelian J; Radu TB; Cabral AD; Sina D; Sedighi A; de Araujo ED; Gunning PT
    Eur J Med Chem; 2020 Sep; 201():112411. PubMed ID: 32615502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unusual zinc-binding mode of HDAC6-selective hydroxamate inhibitors.
    Porter NJ; Mahendran A; Breslow R; Christianson DW
    Proc Natl Acad Sci U S A; 2017 Dec; 114(51):13459-13464. PubMed ID: 29203661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of novel isoform-selective histone deacetylases 5 and 9 inhibitors through combined ligand-based pharmacophore modeling, molecular mocking, and molecular dynamics simulations for cancer treatment.
    Elmezayen AD; Al-Obaidi A; Yelekçi K
    J Mol Graph Model; 2021 Jul; 106():107937. PubMed ID: 34049193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of potential isoform-selective histone deacetylase inhibitors for cancer therapy: a combined approach of structure-based virtual screening, ADMET prediction and molecular dynamics simulation assay.
    Uba AI; Yelekçi K
    J Biomol Struct Dyn; 2018 Sep; 36(12):3231-3245. PubMed ID: 28938863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural and energetic basis for the inhibitory selectivity of both catalytic domains of dimeric HDAC6.
    Sixto-López Y; Bello M; Correa-Basurto J
    J Biomol Struct Dyn; 2019 Nov; 37(18):4701-4720. PubMed ID: 30558483
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular docking-based virtual drug screening revealing an oxofluorenyl benzamide and a bromonaphthalene sulfonamido hydroxybenzoic acid as HDAC6 inhibitors with cytotoxicity against leukemia cells.
    Dawood M; Elbadawi M; Böckers M; Bringmann G; Efferth T
    Biomed Pharmacother; 2020 Sep; 129():110454. PubMed ID: 32768947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hydroxamic acid derivatives as selective HDAC3 inhibitors: computer-aided drug design strategies.
    Patel P; Shrivastava SK; Sharma P; Kurmi BD; Shirbhate E; Rajak H
    J Biomol Struct Dyn; 2024; 42(1):362-383. PubMed ID: 36995068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Computational Approach to Investigate the HDAC6 and HDAC10 Binding Propensity of Psidium guajava-derived Compounds as Potential Anticancer Agents.
    Adewole KE; Ishola AA
    Curr Drug Discov Technol; 2021; 18(3):423-436. PubMed ID: 32357815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of novel leads as potent inhibitors of HDAC3 using ligand-based pharmacophore modeling and MD simulation.
    Kumbhar N; Nimal S; Barale S; Kamble S; Bavi R; Sonawane K; Gacche R
    Sci Rep; 2022 Feb; 12(1):1712. PubMed ID: 35110603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An insight into selective and potent inhibition of histone deacetylase 8 through induced-fit docking, pharmacophore modeling and QSAR studies.
    Kashyap K; Kakkar R
    J Biomol Struct Dyn; 2020 Jan; 38(1):48-65. PubMed ID: 30633630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.